EC
JSPR icon

EntryPoint Capital’s Jasper Therapeutics JSPR Stock Holding History

EntryPoint Capital’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,431
Closed -$223K – 811
2024
Q4 		$223K Buy
+10,431
New +$217K 0.09% 540

Other funds holding JSPR

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

EntryPoint Capital's JSPR Position: Q1 2025 in Review

EntryPoint Capital sold out of Jasper Therapeutics (JSPR) in Q1 2025, closing a stake of 10,431 shares — an estimated $223K sold.

EntryPoint Capital first reported a position in JSPR in Q4 2024 and held it in 1 quarter. The position peaked at $223K in Q4 2024. 68 funds tracked by Wall St. Rank hold JSPR as of Q1 2025.

  • EntryPoint Capital reported no remaining Jasper Therapeutics position as of Q1 2025 after selling out during the quarter.
  • EntryPoint Capital sold 10,431 Jasper Therapeutics shares in Q1 2025, an estimated $223K.
  • EntryPoint Capital first reported a position in Jasper Therapeutics in Q4 2024 and held it in 1 quarter.
  • EntryPoint Capital's Jasper Therapeutics position peaked at $223K in Q4 2024.
  • 68 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2025.

Based on EntryPoint Capital's 13F filing for Q1 2025, filed 14 May 2025.